Potential Lilly Investment Would Further Expand Indianapolis Insulin Manufacturing Operations

Tue Apr 2, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


$180 million investment would support growing diabetes care need
INDIANAPOLIS,  April 2, 2013  /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
today announced that it is working closely with the city on a proposal to invest
an additional  $180 million  in the company's  Indianapolis-based insulin
manufacturing operations. The investment is in addition to the company's 
November 2012  announcement of a  $140 million  expansion of the company's 
Indianapolis  insulin manufacturing operations. Together, the investments would
enable Lilly to meet the growing insulin demand given the rise in diabetes
prevalence across the U.S.  

Lilly also is proposing several other ancillary investment projects totaling
about  $80 million, including a  $40 million  product-inspection center.

The latest  $180 million  proposed investment is two-fold:

* Lilly would add a second insulin cartridge-filling line to the overall scope
of the previously announced expansion, bringing the total to two
insulin-cartridge-filling lines.

* The second piece of the investment would support Lilly's efforts to increase
its insulin-active-ingredient manufacturing capacity. Designed to increase
annual insulin output, this effort would help Lilly boost productivity without
building a new manufacturing plant or adding to its cost structure. The project
also would support Lilly's commitment to maintain the highest quality

"Lilly is making significant investments to support our current portfolio of
diabetes medicines," said  Enrique Conterno, president of Lilly Diabetes. "We
are also continuing to search for new and better treatment options. We have one
of the strongest diabetes pipelines in our history--including four molecules in
late-stage development--that could help support the needs of people with

"We believe  Indianapolis  is a good place for this investment, as we will
continue to benefit from the engaged, committed, and highly skilled work force
we have in this city," said Myles O'Neill, Lilly manufacturing's senior vice
president of global parenteral drug product and delivery devices.  

"Lilly could have made this investment anywhere in the world, but the fact that
it continues to expand in  Indianapolis  is a testament to the great business
climate and workforce in our city," said Mayor  Greg Ballard. "I want to
underscore that despite challenging economic times, in the past six months,
Lilly has announced proposed plans to invest more than a quarter of a billion
dollars in our city and create jobs for many highly skilled people. This is
great news for  Indianapolis."

Construction supporting the additional insulin-cartridge-filling line could be
completed by 2016. During the construction period, construction-trade staffing
would average about 100, with peak employment of approximately 140 workers at
the site.

Construction work in the insulin-active-ingredient production area could be
completed by December and operational by  March 2014. Lilly anticipates that
construction-worker numbers would average around 70 and peak at around 160
during the proposed project. This portion of the investment would enable Lilly
to increase its annual output of insulin active ingredient--the medicine that
goes into the vials and cartridges that patients use.

Once operational, approximately 175 full-time, highly skilled, specialized
technicians, scientists, and engineers would be needed to manage operations in
the cartridge-filling and insulin-active-ingredient manufacturing areas.

Filling insulin cartridges will be a new technology for Lilly's U.S.
manufacturing operations. Lilly sites in the U.S. currently only fill insulin
vials, which are used with a traditional syringe or an insulin pump. Cartridges,
however, are used in insulin "pens," which are growing in popularity in the U.S.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in  Indianapolis, Ind., Lilly provides answers -
through medicines and information - for some of the world's most urgent medical
needs. Additional information about Lilly is available at  www.lilly.com. C-LLY

CAR: CA20257

Refer to:
(317) 433-9899 -  Ed Sagebiel;  sagebiel_edward_g@lilly.com 
(317) 433-3246 -  Andrew McLaughlin;  mclaughlin_andrew@lilly.com

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO  )

SOURCE  Eli Lilly and Company

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.